BJDX (Bluejay Diagnostics, Inc. Common Stock) Stock Analysis - News
Bluejay Diagnostics, Inc. Common Stock (BJDX) is a publicly traded Healthcare sector company. As of May 21, 2026, BJDX trades at $1.81 with a market cap of $1.78M and a P/E ratio of -0.11. BJDX moved +0.00% today. Year to date, BJDX is -32.95%; over the trailing twelve months it is -76.73%. Its 52-week range spans $1.62 to $49.80. Rallies surfaces BJDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in BJDX news today?
Bluejay Diagnostics Enrolls 680 of 750 Patients, Bolsters Symphony Manufacturing Readiness: Bluejay Diagnostics enrolled 680 of 750 patients in its SYMON-II pivotal sepsis IL-6 study and advanced manufacturing readiness with Sanyoseiko, resolving cartridge issues and progressing toward validation. As of March 31, 2026, cash stood at $3.7M with a Q1 net loss of $1.9M as it readies for a 510(k) submission.
Wurth Douglas Clark bought 12.50K (~$25.00K) on Mar 14, 2026.
Dey Indranil bought 12.50K (~$25.00K) on Mar 14, 2026.
CHASE DONALD R bought 12.50K (~$25.00K) on Mar 14, 2026.
BJDX Analyst Consensus
BJDX analyst coverage data. Average price target: $0.00.
Common questions about BJDX
What changed in BJDX news today?
Bluejay Diagnostics Enrolls 680 of 750 Patients, Bolsters Symphony Manufacturing Readiness: Bluejay Diagnostics enrolled 680 of 750 patients in its SYMON-II pivotal sepsis IL-6 study and advanced manufacturing readiness with Sanyoseiko, resolving cartridge issues and progressing toward validation. As of March 31, 2026, cash stood at $3.7M with a Q1 net loss of $1.9M as it readies for a 510(k) submission.
Does Rallies summarize BJDX news?
Yes. Rallies summarizes BJDX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is BJDX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BJDX. It does not provide personalized investment advice.
